Patents by Inventor Nicolas Guisot

Nicolas Guisot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds useful as kinase inhibitors
    Patent number: 11826351
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: November 28, 2023
    Assignee: Loxo Oncology Inc.
    Inventor: Nicolas Guisot
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20230372298
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 23, 2023
    Inventor: Nicolas GUISOT
  • Compounds useful as kinase inhibitors
    Patent number: 11471441
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: October 18, 2022
    Assignee: Loxo Oncology Inc.
    Inventor: Nicolas Guisot
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20220062239
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 3, 2022
    Inventor: Nicolas GUISOT
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20210093611
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: December 15, 2020
    Publication date: April 1, 2021
    Inventor: Nicolas GUISOT
  • Compounds useful as kinase inhibitors
    Patent number: 10918622
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: February 16, 2021
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Compounds useful as kinase inhibitors
    Patent number: 10695323
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 30, 2020
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
    Patent number: 10611766
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 7, 2020
    Assignee: Loxo Oncology Inc.
    Inventor: Nicolas Guisot
  • Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase
    Patent number: 10538524
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 21, 2020
    Assignee: Loxo Oncology Inc.
    Inventors: Mathew Calder, Nicolas Guisot
  • Compounds useful as kinase inhibitors
    Patent number: 10464905
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: November 5, 2019
    Assignee: Loxo Oncology Inc.
    Inventor: Nicolas Guisot
  • Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
    Patent number: 10399989
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: September 3, 2019
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
    Patent number: 10399990
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: September 3, 2019
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • Compounds useful as kinase inhibitors
    Patent number: 10342780
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: July 9, 2019
    Assignee: Loxo Oncology, Inc.
    Inventor: Nicolas Guisot
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20190135762
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: December 16, 2016
    Publication date: May 9, 2019
    Inventor: Nicolas Guisot
  • Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase
    Publication number: 20190119281
    Abstract: This invention relates to compounds of formula (I). The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: May 11, 2018
    Publication date: April 25, 2019
    Inventors: Mathew Calder, Nicolas Guisot
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20190000806
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: August 27, 2018
    Publication date: January 3, 2019
    Inventor: Nicolas Guisot
  • PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20180362537
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventor: Nicolas Guisot
  • PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20180362533
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventor: Nicolas Guisot
  • COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20180362512
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 20, 2018
    Inventor: Nicolas Guisot
  • PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20180298008
    Abstract: This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
    Type: Application
    Filed: September 16, 2016
    Publication date: October 18, 2018
    Inventor: Nicolas Guisot